PGx Clinical Pathway Development Study: Version 1.0

  • Research type

    Research Study

  • Full title

    Pharmacogenetic (PGx) Clinical Pathway Development Study

  • IRAS ID

    259157

  • Contact name

    Essra Youssef

  • Contact email

    e.youssef@uea.ac.uk

  • Sponsor organisation

    University of East Anglia

  • Duration of Study in the UK

    0 years, 2 months, 31 days

  • Research summary

    Many of us are now aware that our genes can play a role in our appearance, susceptibility to disease and even our personality. Our genes can also play a role in how we react to medicines. One of the most widely studied ways in which we can differ is in our genes that control how our liver processes medicines. The study and practice of identifying these genes is called pharmacogenomics (PGx). PGx testing is helpful for doctors and pharmacists to choose medicines that are best for each patient and in what amount so they are more likely to work and less likely to cause side effects.
    PGx testing is available in the USA, Canada, Australia and other countries in the EU. Within the UK, we don’t have access to this technology so information to support how best to fit it into our current healthcare systems is lacking. This presents a challenge to designing future studies that can measure the cost-effectiveness of PGx testing which is a necessity for adoption by the NHS.
    30 patients from three different settings (2 General practices, 2 Hospitals and 1 Mental Health Trust) will be able to access PGx testing through their doctor/pharmacist or nurse. We will develop potential ways in which PGx testing can be delivered at each site. We will then interview doctors, pharmacists, nurses and patients to understand what some of the barriers and facilitators are for PGx testing from a UK perspective.
    We will produce a publication with the results from what we have learned. The information from this study will be used to design a future study to answer our question about the feasibility of PGx testing.

  • REC name

    East of Scotland Research Ethics Service REC 1

  • REC reference

    19/ES/0116

  • Date of REC Opinion

    30 Sep 2019

  • REC opinion

    Unfavourable Opinion